{
  "docId": "019de071-3fcc-709d-bd81-493d670a1b54",
  "docSlug": "75c0ef2784bf914c01a48398bea9ca14",
  "documentTitle": "Caribou Biosciences | IPO Presentation Deck | 44 slides",
  "authorId": "caribou-biosciences",
  "authorName": "Caribou Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7744917,
  "pageNumber": 9,
  "pageCount": 44,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses a before-after-bridge style logic to frame the problem (efficacy challenge) and the company's solution (persistence).",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-3fcc-709d-bd81-493d670a1b54/9",
  "deckHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54",
  "deckJsonHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54.json",
  "deckAnchorHref": "/decks/019de071-3fcc-709d-bd81-493d670a1b54#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Persistence is the solution",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "239ba4af-f529-4f17-9355-386366097c64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.75,
        "y": 0.25
      },
      "kind": "callout",
      "text": "... but efficacy remains a challenge: Rapid rejection by immune system, Lower efficacy in solid tumors than liquid tumors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2637204f-3692-4112-9334-f83c963959fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Autologous therapy vs Allogeneic therapy comparison",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b75e80a-a465-447e-81d5-7d82a8394e5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "Limited patient access, Long vein-to-vein times, Not all patients eligible, Single dose, Bridging therapy often required, Manufacturing complexity, Variable potency, High production costs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51ec4809-8d5a-4686-8d9b-9aa78efbca03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.55
      },
      "kind": "list",
      "text": "Broad patient access, Immediate availability, Suitable for most patients, Repeat dosing possible, Bridging therapy not required, Off-the-shelf availability, More uniform T cells from healthy donors, More efficient and cost-effective manufacturing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "926b209d-6965-481e-94f7-3fd6c7708c3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "We believe persistence is the key to unlocking the full potential of allogeneic cell therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77c3f627-09e4-4fb2-a2b3-a7120af47cc8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "f7f99205-5947-4c29-b3c5-ca42f3765a04",
      "evidence": "Contrasts current therapy limitations with the company's proposed solution.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "38684ac5-ccf1-4ef3-bd5a-a56e574a5ffc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The problem statement is presented on page 9",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 14,
      "from": 7,
      "beatId": "630e1d28-eeca-4ead-af41-7557fcaa17ed",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The solution is presented on pages 7-14",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "24942973-5728-4b19-9656-9170f2cce1f1",
      "evidence": "The loop follows the golden circle structure",
      "position": 1,
      "objective": "To explain the why, how, and what of chRDNA technology",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    },
    {
      "to": 9,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d080d1e4-5925-4f3b-8a41-0527450417ff",
      "evidence": "The loop highlights the cost of inaction",
      "position": 2,
      "objective": "To highlight the need for improved allogeneic cell therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}